Tags: Drug.

MK-2048 is a second generation integrase inhibitor intended to be used against HIV infection. It is superior to the first available integrase inhibitor raltegravir in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). It is being developed by Merck & Co.

MK-2048.svg
ATC prefix
none
IUPAC name
(6S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N6-dimethyl-19-dioxo-126789-hexahydropyrazino‌[1′2′:15]‌pyrrolo‌[23-d]‌pyridazine-4-carboxamide
PubChem
11554427

Loading...

This page contains content from the copyrighted Wikipedia article "MK-2048"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.